Scribe Therapeutics, Inc. (SCTX) stock
SCTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$15.77+0.40 (+2.60%)
Close on Nov 17, 2026Market cap $39.19MP/E –Yield –
Scribe Therapeutics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
No ev/ebitda figures for Scribe Therapeutics
Scribe Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?